Literature DB >> 15886239

Tissue transglutaminase at embryo-maternal interface.

Maryam Kabir-Salmani1, Shigetatsu Shiokawa, Yoshihiro Akimoto, Keiji Sakai, Ken Sakai, Mitsutoshi Iwashita.   

Abstract

CONTEXT: Tissue transglutaminase (tTG) has a high affinity for fibronectin (FN) and is a coreceptor of both beta1 and beta3 integrin subunits. Considering the notion that FN and integrins have critical roles during the implantation process, this study was undertaken to elucidate the expression pattern and the potential physiological function of tTG at the embryo-maternal interface.
METHODS: The primary cultures of human placentas from 15 legal elective abortions at the first trimester of normal pregnancies and endometrial biopsies of 12 female patients in the midluteal phase as well as normal trophoblastic cell lines (CRL) were employed to address these issues using several approaches, such as scanning and transmission electron microscopies, immunostaining for light and electron microscopies, western blotting, and function assays using GRGDSP hexapeptide and an antibody against tTG.
RESULTS: The results demonstrated tTG expression on uterine pinopodes and lamellipodia of extravillous trophoblasts. The colocalization of tTG with beta1 and beta3 integrins and its interaction with alpha(v)beta3 integrin and integrin-associated proteins at focal adhesions of the extravillous trophoblasts were illustrated in the results of immunofluorescence, immunoblot, and coimmunoprecipitation studies. Furthermore, function assays revealed that tTG mediated the adhesion and spread of the placental cells on intact FN-coated and 42- and 110-kDa FN fragment-coated wells.
CONCLUSION: In conclusion, our findings demonstrated for the first time that tTG actively participates in adhesion events at the embryo-maternal interface through its interaction with FN, at least in part, by activating integrin-signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886239     DOI: 10.1210/jc.2005-0240

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.

Authors:  M Cheng; P He; J Fu
Journal:  J Hum Hypertens       Date:  2016-05-12       Impact factor: 3.012

2.  Magnetic Resonance Imaging Reveals Distinct Roles for Tissue Transglutaminase and Factor XIII in Maternal Angiogenesis During Early Mouse Pregnancy.

Authors:  Gadi Cohen; Ron Hadas; Rachele Stefania; Amerigo Pagoto; Shifra Ben-Dor; Fortune Kohen; Dario Longo; Michal Elbaz; Nave Dekel; Eran Gershon; Silvio Aime; Michal Neeman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-13       Impact factor: 8.311

3.  Extracellular transglutaminase 2 has a role in cell adhesion, whereas intracellular transglutaminase 2 is involved in regulation of endothelial cell proliferation and apoptosis.

Authors:  C Nadalutti; K M Viiri; K Kaukinen; M Mäki; K Lindfors
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

4.  Effects of dietary quercetin on female fertility in mice: implication of transglutaminase 2.

Authors:  Kelly E Beazley; Maria Nurminskaya
Journal:  Reprod Fertil Dev       Date:  2016-06       Impact factor: 2.311

5.  The membrane-spanning domain of CD98 heavy chain promotes alpha(v)beta3 integrin signals in human extravillous trophoblasts.

Authors:  Maryam Kabir-Salmani; Michiko N Fukuda; Masami Kanai-Azuma; Nesar Ahmed; Shigetatsu Shiokawa; Yoshihiro Akimoto; Keiji Sakai; Seishi Nagamori; Yoshikatsu Kanai; Kazuhiro Sugihara; Mitsutoshi Iwashita
Journal:  Mol Endocrinol       Date:  2007-11-21

Review 6.  Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family.

Authors:  Benedict Onyekachi Odii; Peter Coussons
Journal:  ScientificWorldJournal       Date:  2014-03-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.